Verici Dx successfully concludes the bookbuild for its placing to raise approximately £6.22 million
January 2024
Verici Dx is an AIM listed developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
Placing and Retail Offer
24th January 2024, the company announced that it had successfully concluded the Bookbuild for its Placing to raise gross proceeds of approximately £6.22 million through the placing of 69,111,111 Placing Shares with existing and new investors at the Issue Price of 9.0 pence and on 25th January, it announced the launch of a Retail Offer to raise up to a further £0.28 million.
The Perivan shareholder communications team was delighted to work with Singer Capital Markets who acted as Nominated Adviser and Shoosmiths who acted as legal adviser to Verici Dx on the shareholder documentation which was successfully completed and posted to qualifying shareholders on 26th January 2024.
Perivan is the market leader for admission document production and specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
